Bulk Pharmaceutical API Sources for DROXIA

Bulk Pharmaceutical API Sources for DROXIA

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		H8627_SIGMA
Tyger Scientific		H20210
Molport		MolPort-000-003-971
TCI (Tokyo Chemical Industry)		H0310
Vitas-M Laboratory		STL145898
Vitas-M Laboratory		BBL009928
Amadis Chemical		A805636

Droxia Bulk API Suppliers: Global Landscape and Sourcing Considerations

Last updated: February 19, 2026

This analysis identifies key global suppliers of Droxia (hydroxyurea) bulk active pharmaceutical ingredient (API). It examines market players, manufacturing capabilities, regulatory compliance, and pricing indicators to inform strategic sourcing decisions for pharmaceutical manufacturers.

Who Are the Primary Global Manufacturers of Droxia API?

The global Droxia API market is characterized by a consolidated supplier base, with production concentrated in regions with established pharmaceutical manufacturing infrastructure and favorable cost structures. Key players include both generic API manufacturers and vertically integrated pharmaceutical companies.

Major API Suppliers:

• Novartis AG: The originator of Droxia, Novartis continues to be a significant player, though its primary focus has shifted to branded product sales. Their internal API production capabilities likely serve a portion of their global supply needs.
• Teva Pharmaceutical Industries Ltd.: A dominant force in the generic pharmaceutical market, Teva manufactures and supplies a broad range of APIs, including hydroxyurea. Their global manufacturing footprint allows for significant production volumes.
• Sun Pharmaceutical Industries Ltd.: India's largest pharmaceutical company, Sun Pharma is a major producer of generic APIs and finished dosage forms. They operate multiple API manufacturing facilities compliant with international regulatory standards.
• Mylan N.V. (now Viatris): Viatris, formed by the merger of Mylan and Pfizer's Upjohn division, maintains a substantial API manufacturing and supply chain. Hydroxyurea is within their portfolio of generic APIs.
• Dr. Reddy's Laboratories Ltd.: Another leading Indian pharmaceutical company, Dr. Reddy's has a strong API division with global reach, supplying hydroxyurea to various markets.
• Amneal Pharmaceuticals LLC: A US-based pharmaceutical company with expanding API manufacturing capabilities, Amneal is a notable supplier in North America.
• Accord Healthcare (Intas Pharmaceuticals): As part of the Intas Pharmaceuticals group, Accord Healthcare is a significant supplier of generic APIs and finished drugs, including hydroxyurea.

Geographic Concentration of API Manufacturing:

• India: Holds a substantial share of global generic API production due to a well-developed chemical synthesis industry, skilled workforce, and cost advantages. Companies like Sun Pharma, Dr. Reddy's, and numerous mid-sized manufacturers are based here.
• China: Remains a critical global API manufacturing hub, though regulatory scrutiny and increased environmental compliance costs have influenced production dynamics. Several Chinese API manufacturers supply hydroxyurea.
• Europe: While less dominant in high-volume generic API production compared to Asia, European manufacturers, particularly those with specialized synthesis capabilities or serving regulated markets directly, are present.
• North America: A growing presence of API manufacturing is observed, driven by reshoring initiatives and companies like Amneal investing in domestic production.

What Are the Regulatory and Quality Standards for Droxia API?

Sourcing Droxia API necessitates strict adherence to international regulatory requirements to ensure product quality, safety, and efficacy. Compliance with Good Manufacturing Practices (GMP) is paramount.

Key Regulatory Bodies and Standards:

• U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must comply with FDA's cGMP regulations (21 CFR Parts 210 and 211). FDA conducts site inspections of API manufacturing facilities.
• European Medicines Agency (EMA): API suppliers for the European Union must meet EU GMP guidelines, often verified through inspections by national competent authorities. Certificates of Suitability (CEP) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) are crucial.
• Pharmaceuticals and Medical Devices Agency (PMDA) - Japan: Japanese regulatory standards require strict adherence to Japanese GMP.
• World Health Organization (WHO) GMP: A global benchmark often adopted by regulatory agencies in developing countries.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines, particularly Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), provide a harmonized framework.

Quality Documentation Required:

• Drug Master File (DMF): A confidential submission to regulatory authorities (e.g., FDA, Health Canada) detailing the chemistry, manufacturing, and controls of the API. This allows drug product manufacturers to reference the API's quality data without disclosing proprietary information to their competitors.
• Certificate of Analysis (CoA): A document accompanying each batch of API, certifying that it meets predefined specifications for purity, potency, identity, and other quality attributes.
• Site Master File (SMF): Provides an overview of the API manufacturing site, including its operations, quality systems, and regulatory history.
• Impurity Profiling: Comprehensive data on known and potential impurities, including genotoxic impurities, is critical.

What Are the Key Manufacturing Processes and Technical Specifications for Droxia API?

The synthesis of hydroxyurea involves established chemical processes. Manufacturers must control these processes to ensure consistent API quality and to minimize impurities.

Common Synthesis Routes:

The most common route for hydroxyurea synthesis involves the reaction of hydroxylamine (often as hydroxylamine sulfate or hydrochloride) with urea under specific reaction conditions.

• Reaction of Hydroxylamine Salts with Urea:
  • Urea is reacted with a hydroxylamine salt in the presence of a base or under controlled pH conditions to facilitate the nucleophilic addition.
  • Reaction conditions (temperature, solvent, reaction time, pH) are critical for optimizing yield and minimizing by-products.
  • Subsequent purification steps, such as recrystallization, are employed to achieve the desired API purity.

Typical API Specifications (Example - may vary by pharmacopeia):

Parameter	Specification Range / Limit
Appearance	White crystalline powder
Assay (Hydroxyurea)	Not less than 99.0% and not more than 101.0% (on dried basis)
Identification	Conforms to spectroscopic (e.g., IR) and chemical tests
Melting Range	155°C - 157°C
Loss on Drying	Not more than 1.0%
Residue on Ignition	Not more than 0.1%
Heavy Metals	Not more than 10 ppm
Related Substances	Individual impurities: Not more than 0.1%
	Total impurities: Not more than 0.5%
Specific Impurities	E.g., Urea, Biuret, Cyanamide - stringent limits apply
Particle Size	May be specified for dissolution rate considerations

(Source: Based on typical USP/EP monographs for Hydroxyurea)

Considerations for API Manufacturing:

• Impurity Control: Hydroxyurea can degrade to form impurities like cyanates, biuret, and ammelide. Rigorous process validation and in-process controls are necessary to limit their formation and removal.
• Stability: API stability under storage conditions is critical. Manufacturers must provide data on retest periods and storage recommendations.
• Polymorphism: While less common for hydroxyurea compared to some other APIs, control over crystal form may be important for dissolution and bioavailability.

What Are the Market Dynamics and Pricing Trends for Droxia API?

The Droxia API market is largely driven by the demand for generic hydroxyurea finished dosage forms. Pricing is influenced by raw material costs, manufacturing efficiencies, competitive landscape, and regulatory compliance burdens.

Factors Affecting Pricing:

• Raw Material Costs: Fluctuations in the cost of key precursors like hydroxylamine salts and urea directly impact API production costs.
• Manufacturing Scale and Efficiency: Larger-scale production generally leads to lower per-unit costs. Manufacturers with optimized synthesis routes and efficient purification processes have a cost advantage.
• Regulatory Compliance Costs: Investment in GMP-compliant facilities, quality control systems, and regulatory filings (e.g., DMF submissions and updates) adds to the overall cost.
• Competition: A fragmented supplier base, particularly from India and China, contributes to competitive pricing.
• Geopolitical Factors: Supply chain disruptions, trade policies, and currency exchange rates can influence pricing and availability.
• Demand from Finished Dosage Form Manufacturers: The volume of orders placed by generic drug companies for Droxia capsules or tablets is a primary driver of API demand.

Estimated Price Ranges (Indicative):

Indicative pricing for Droxia API can range significantly based on volume, supplier, purity grades, and contractual terms.

• Bulk Contract Pricing (Large Volume): $50 - $150 per kilogram.
• Smaller Volume / Spot Market: $150 - $300+ per kilogram.

(Note: These are rough estimates and can vary widely. Actual prices are subject to negotiation and specific supplier agreements.)

Market Trends:

• Increasing Demand for Generics: The patent expiry of branded hydroxyurea products has led to a sustained demand for generic versions, driving API consumption.
• Supply Chain Resilience: Recent global events have highlighted the importance of supply chain diversification and resilience, potentially favoring manufacturers with multiple production sites or in different geographic regions.
• Focus on Quality and Compliance: Regulatory agencies worldwide are intensifying their scrutiny of API quality and manufacturing practices, leading to consolidation among suppliers and higher compliance standards.
• Consolidation of Manufacturers: Mergers and acquisitions within the pharmaceutical industry can impact the supplier landscape for APIs.

How Can Pharmaceutical Companies Strategically Source Droxia API?

Effective sourcing of Droxia API requires a multi-faceted approach that balances cost, quality, supply reliability, and regulatory compliance.

Key Sourcing Strategies:

1. Supplier Qualification:

   • Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities to assess GMP compliance, quality systems, and production capacity.
   • Review regulatory history, including any FDA warning letters, import alerts, or EMA inspection findings.
   • Evaluate supplier financial stability and business continuity plans.

2. Quality Assurance:

   • Ensure suppliers have robust quality management systems in place.
   • Verify that DMFs are up-to-date and accepted by target regulatory authorities.
   • Establish clear specifications and testing protocols for incoming API batches.

3. Supply Chain Diversification:

   • Avoid over-reliance on a single supplier or geographic region.
   • Identify secondary and tertiary suppliers to mitigate risks of supply disruption.
   • Consider suppliers with multiple manufacturing sites.

4. Contractual Agreements:

   • Negotiate clear contracts that define quality standards, delivery schedules, pricing, change control procedures, and intellectual property protection.
   • Include provisions for force majeure events and dispute resolution.

5. Technical Collaboration:

   • Engage with suppliers to understand their manufacturing processes and impurity profiles.
   • Collaborate on process improvements or troubleshooting when necessary.

6. Cost Analysis:

   • Go beyond the per-kilogram price. Consider total cost of ownership, including freight, quality control testing, inventory holding costs, and potential costs associated with non-compliance or supply disruptions.
   • Understand the cost drivers for each supplier.

Risk Mitigation:

• Geopolitical Risk Assessment: Monitor political stability, trade policies, and potential for supply chain disruptions in key manufacturing regions.
• Regulatory Intelligence: Stay abreast of evolving regulatory requirements in target markets.
• Inventory Management: Maintain appropriate inventory levels to buffer against short-term supply fluctuations, balancing carrying costs with risk.

Key Takeaways

• The Droxia API market is dominated by a limited number of large generic API manufacturers, with significant production capacity located in India and China.
• Strict adherence to international GMP standards (FDA, EMA) and comprehensive quality documentation (DMFs, CoAs) are non-negotiable for API sourcing.
• Hydroxyurea synthesis requires careful control over process parameters to manage impurities. Key specifications focus on assay, related substances, and heavy metals.
• API pricing is competitive, influenced by raw material costs, manufacturing scale, and regulatory compliance, with indicative bulk prices ranging from $50-$150 per kilogram.
• Strategic sourcing involves robust supplier qualification, supply chain diversification, strong contractual agreements, and a thorough understanding of total cost of ownership beyond the per-unit price.

Frequently Asked Questions

1. What is the primary regulatory pathway for a new Droxia API supplier to enter the U.S. market? A new supplier must typically file a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) and ensure their manufacturing facilities comply with current Good Manufacturing Practices (cGMP). Pharmaceutical companies seeking to use the API will then reference this DMF in their own drug product applications.

2. How can a pharmaceutical company assess the long-term supply reliability of a Droxia API manufacturer? Reliability assessment involves evaluating the manufacturer's historical performance, financial stability, production capacity utilization, business continuity plans, and diversification of their own raw material sources. Site audits and supply agreements with clear performance metrics are essential.

3. Are there specific impurity concerns with Droxia API that manufacturers must address? Yes, hydroxyurea can degrade or be synthesized with impurities such as urea, biuret, ammelide, and cyanates. Manufacturers must demonstrate rigorous control over these and other process-related impurities through validated analytical methods and tight process controls.

4. What is the typical lead time for ordering Droxia API in bulk? Lead times can vary but generally range from 8 to 16 weeks for large bulk orders, depending on the supplier's current production schedule, raw material availability, and the need for specific batch release testing. Expedited orders may incur additional costs.

5. Does the origin country of the Droxia API significantly impact its acceptance by regulatory agencies like the FDA or EMA? While the origin country itself is not a disqualifier, the regulatory track record and compliance history of the manufacturing site in that country are critical. Facilities in India and China are widely used but are subject to rigorous FDA and EMA inspections and scrutiny. Compliance with international GMP standards is the primary determinant.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations Title 21 Part 210/211. Retrieved from [FDA Website - specific CFR link needed for official citation] [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [EMA Website - specific GMP link needed for official citation] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1999). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from [ICH Website - specific Q7 link needed for official citation] [4] United States Pharmacopeia. (Current Edition). Monograph: Hydroxyurea. In The United States Pharmacopeia and The National Formulary. [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM Website - specific CEP link needed for official citation]